[Modulation of integrin alpha-v-beta-1 expression on human tumor cells by leukemia inhibitory factor (LIF) and oncostatin M (OSM)].
Integrins belong to a large family of heterodimeric membrane glycoproteins which mediate cell-cell or cell-extracellular matrix interactions. These interactions could play a major role during the migration of tumor cells across the extracellular matrix and vascular endothelium and would thus appear to be a requisite for the metastatic process. Treatment of the Foss human melanoma cell line with LIF or OSM, two cytokines involved in acute-phase response, increased the expression of membrane alpha v beta 1 by 1.5-2 fold. The same phenomenon was observed on the SK-N-SH human neuroblastoma cell line. This modulation, which was inhibited by specific monoclonal antibodies against alpha v or beta 1 integrin subunits, was concomitant with improved tumor cell attachment to the fibronectin matrix. Similar results were obtained after TNF-alpha treatment. Our findings demonstrate the ability of LIF and OSM to modulate tumor cell capacity to adhere to the matrix component, suggesting a potential role for these cytokines in modulation of tumoral progression.
Heymann
D
D
Inserm U211, Institut de Biologie, Nantes, France.
Harb
J
J
Ringeard
S
S
Blanchard
F
F
Lassort
D
D
Raher
S
S
Godard
A
A
D000970:Antineoplastic Agents / Q000494:pharmacology*; D006131:Growth Inhibitors / Q000494:pharmacology*; D006801:Humans; D016023:Integrins / Q000378:metabolism*; D008545:Melanoma / Q000473:pathology / Q000503:physiopathology; D009447:Neuroblastoma / Q000473:pathology / Q000503:physiopathology; D017469:Receptors, Fibronectin / Q000378:metabolism*; D019030:Receptors, Vitronectin; D014407:Tumor Cells, Cultured; D015854:Up-Regulation / Q000187:drug effects*
D000970:Antineoplastic Agents; D006131:Growth Inhibitors; D016023:Integrins; D017469:Receptors, Fibronectin; D019030:Receptors, Vitronectin; C094340:integrin alphavbeta1
Modulation de l'expression de l'intégrine alpha-v-beta-1 à la surface des cellules cancéreuses humaines par le leukemia inhibitory factor (LIF) et l'oncostatine M (OSM).